Results 141 to 147 of about 662,207 (147)

TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity

British Journal of Pharmacology, 2011
H Tomoike
exaly  

Modification on the -glucoside of Sergliflozin-A: A new strategy for SGLT2 inhibitor design

Bioorganic and Medicinal Chemistry Letters, 2016
Jie Shen, Peng George Wang
exaly  

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment

Diabetes, Obesity and Metabolism, 2014
M Mattheus, U C Broedl
exaly  

Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials

Diabetologia, 2016
Yiqing Song, Xi Zhang, Jingjing Zhang
exaly  

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

Biopharmaceutics and Drug Disposition, 2014
Takeo Nakanishi, Ikumi Tamai, Yukihiro Chino   +2 more
exaly  

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

Diabetes, Obesity and Metabolism, 2013
J Rosenstock, S Hantel
exaly  

In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor

Xenobiotica, 2017
Yukihiro Chino, Jun-Ichi Yamaguchi
exaly